Characteristics of patients with Alzheimer’s disease and controls
| Controls | Patients | |||
|---|---|---|---|---|
| *p<0.001, Wilcoxon-Mann-Whitney U test. | ||||
| ADRDA, Alzheimer’s Disease and Related Disorders Association; CAMCOG, Cambridge cognitive assessment; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CSF, cerebrospinal fluid; IQR, interquartile range; MMSE, mini-mental state examination; NINCDS, National Institute of Neurological and Communicative Disorders and Stroke; NSAID, non-steroidal anti-inflammatory drug. | ||||
| Total number of subjects | 35 | 33 | ||
| Women | 17 | 22 | ||
| Clinical diagnosis (NINCDS/ADRDA) | 35 negative | 33 probable | ||
| Age at first visit: median (interquartile range, IQR) | 70.4 (65.7 to 76.8) | 71.0 (64.9 to 77.3) | ||
| Pathological diagnosis (CERAD) | 4 negative | 25 definite | ||
| 2 possible | 1 probable | |||
| Learning memory subscale of CAMCOG (median, IQR) first visit | 14.0 (13 to 16)* | 4.0 (2.8 to 7.3)* | ||
| MMSE (median, IQR) first visit | 28 (27 to 30)* | 19.0 (15.5 to 22.0)* | ||
| Sporadic users of low dose aspirin | ||||
| Initial visit | 6 | 3 | ||
| At one or more visits during study period | 17 | 11 | ||
| Sporadic users of NSAIDs (ibuprofen, diclofenac) | 3 | 1 | ||
| APOE4 allelic frequency | 0.10 | 0.46 | ||
| CSF PGE2 (pg/ml), first visit: median (IQR) | 11.0 (6.4 to 14.6) | 7.5 (3.3 to 13.0) | ||